T. Rowe Price Investment Management’s BioNTech BNTX Stock Holding History

T. Rowe Price Investment Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$192M	Sell	2,065,456 -3,790,617	-65%	-$357M	0.13%	185
2026 Q1	$520M	Buy	5,856,073 +1,371,474	+31%	+$141M	0.36%	74
2025 Q4	$427M	Sell	4,484,599 -349,043	-7%	-$35.2M	0.27%	93
2025 Q3	$477M	Buy	4,833,642 +1,235,170	+34%	+$132M	0.29%	90
2025 Q2	$383M	Buy	3,598,472 +3,512,318	+4,077%	+$355M	0.24%	114
2025 Q1	$7.85M	Buy	86,154 +32,818	+62%	+$3.67M	0.01%	570
2024 Q4	$6.08M	Buy	+53,336	New	+$6.09M	﹤0.01%	569

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

T. Rowe Price Investment Management's BNTX Position: Q2 2026 in Review

T. Rowe Price Investment Management reduced its BioNTech (BNTX) stake by 65% in Q2 2026, selling an estimated $357M and leaving 2,065,456 shares worth $192M. The position accounts for 0.13% of the portfolio, ranked #185.

T. Rowe Price Investment Management first reported a position in BNTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $520M in Q1 2026. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

T. Rowe Price Investment Management held 2,065,456 shares of BioNTech worth $192M as of Q2 2026.
T. Rowe Price Investment Management sold 3,790,617 BioNTech shares in Q2 2026, an estimated $357M.
BioNTech made up 0.13% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #185 holding.
T. Rowe Price Investment Management first reported a position in BioNTech in Q4 2024 and has held it in 7 quarters since.
T. Rowe Price Investment Management's BioNTech position peaked at $520M in Q1 2026.
282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.